01—Abstract
Summary
Summary of the 10-Q filed October 29, 2026. Cited figures are marked; the original filing is the authoritative source.
Tenet Healthcare Corporation reported a strong third quarter of 2026.
Net operating revenues were $5.631 billiona, up from $5.289 billion a year earlier, a 6.5% increase. The Hospital Operations segment grew 6.1%, driven by higher patient volumes and pricing strength, partly offset by a less favorable payer mix. Ambulatory Care revenues rose 7.5%.
Operating income increased 96.9% to $1.750 billionb, and net income available to Tenet common shareholders rose to $1.000 billion from $342 million. Diluted earnings per share were $12.41, compared with $3.86. Results were boosted by $646 million of revenue from contract termination, which includes a $233 million cumulative catch-up adjustment tied to the CHI Agreements for Conifer's revenue cycle management services.
The company now expects to substantially complete that transition by October 30, 2026, rather than December 31, 2026. For the nine months ended September 30, 2026, net cash provided by operating activities was $3.507 billionc, compared with $2.809 billion, including $540 million of contract termination payments received. Cash and cash equivalents were $2.674 billion at quarter-end.
Tenet issued $2.000 billiond of 6.250% senior unsecured notes due 2034 and used the proceeds, together with cash on hand, to redeem all $1.500 billion of its 5.125% senior secured first lien notes due 2027 and $500 million of its 6.125% senior unsecured notes due 2028. Repurchases of common stock totaled $1.615 billion for the nine months, and $1.875 billion remained available under the repurchase program at September 30, 2026. The filing also flags risks from federal and state healthcare policy.
Management said that admissions among patients with coverage through health insurance exchanges have declined in 2026, creating an unfavorable payer mix shift. The company stated it cannot yet estimate the impact of the One Big Beautiful Bill Act, whose most consequential provisions take effect beginning in 2027. The company also reported that there were no material changes to the risk factors in its 2025 Form 10-K.
02—Key points
Key Highlights
- Q3 2026 net operating revenues were $5.631 billion, up 6.5% from $5.289 billion, with Hospital Operations up 6.1% and Ambulatory Care up 7.5%.
- Q3 2026 revenue from contract termination was $646 million, including a $233 million cumulative catch-up adjustment under the CHI Agreements; nine-month contract termination revenue was $1.472 billion.
- Q3 2026 operating income rose 96.9% to $1.750 billion, and diluted EPS was $12.41 versus $3.86 in Q3 2025.
- Nine-month net cash from operating activities was $3.507 billion, up from $2.809 billion, aided by $540 million of contract termination payments received.
- Tenet issued $2.000 billion of 6.250% notes due 2034 and redeemed $1.500 billion of 5.125% secured first lien notes due 2027 and $500 million of 6.125% notes due 2028.
- Nine-month share repurchases totaled $1.615 billion, with $1.875 billion remaining under the program at September 30, 2026; 79,588 thousand shares were outstanding as of October 23, 2026.
- Management reported a decrease in exchange-coverage admissions in 2026 and cited the OBBBA as a source of future uncertainty for Medicaid funding and coverage.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2026filed October 29, 2026Financial Statements
Q3 FY2026 against Q3 FY2025
| Line item | Q3 FY2026Q3 FY2025 | Change |
|---|---|---|
| Revenue | $5.63B$5.29B | +6.5% |
| Operating Income | $1.75B$889.00M | +96.9% |
| Net Income | $1.00B$342.00M | +192.4% |
| EPS (Basic) | $12.48$3.89 | +220.8% |
| EPS (Diluted) | $12.41$3.86 | +221.5% |
| Shares Outstanding (Basic) | 80.13M87.95M | −8.9% |
| Shares Outstanding (Diluted) | 80.60M88.61M | −9.0% |
05—Questions
Frequently Asked Questions
What drove the large increase in third-quarter profitability?
Net operating revenues rose $342 million, or 6.5%, to $5.631 billion, and Q3 2026 revenue from contract termination of $646 million, including a $233 million cumulative catch-up adjustment, contributed significantly. Operating income increased to $1.750 billion from $889 million, and net income available to common shareholders rose to $1.000 billion from $342 million.
Is the contract termination revenue recurring?
The filing describes it as revenue from the CHI Agreements, which concluded the Conifer master services agreement early. The company expects to substantially complete the revenue cycle management transition by October 30, 2026, rather than December 31, 2026. The filing also states that the majority of the fixed-fee revenue for the three months ending December 31, 2026 relates to the CHI Agreements, and that $734 million of revenue cycle management performance obligations remained unsatisfied at quarter-end.
How is Tenet managing its debt and liquidity?
Tenet had $2.674 billion of cash and cash equivalents at September 30, 2026, and $12.662 billion of senior notes outstanding. It had $1.900 billion of borrowing availability under its Credit Agreement with no cash borrowings. The 2034 notes refinanced near-term maturities, and the company stated it was in compliance with all covenants at quarter-end.
What policy risks does the filing highlight for future results?
The filing cites a decline in admissions among exchange-coverage patients in 2026, which shifted payer mix unfavorably. It also notes that the One Big Beautiful Bill Act, with most key provisions effective beginning in 2027, could reduce Medicaid payments and supplemental payments, and that the company cannot yet estimate its impact. The filing also notes proposed Medicare OPPS changes that would yield an average 7.4% net increase for proprietary hospitals in CY 2027.
06—Continue